Cell type-specific delivery of short interfering RNAs by dye-functionalised theranostic nanoparticles

Nature Communications

Volumn 5, Issue , 2014, Pages

  Press, Adrian T ^a,b   Traeger, Anja ^b   Pietsch, Christian ^b   Mosig, Alexander ^a   Wagner, Michael ^b   Clemens, Mark G ^a,c   Jbeily, Nayla ^a   Koch, Nicole ^a   Gottschaldt, Michael ^b   Bézière, Nicolas ^d   Ermolayev, Volodymyr ^d   Ntziachristos, Vasilis ^d   Popp, Jürgen ^a,b,e   Kessels, Michael M ^a   Qualmann, Britta ^a,b   Schubert, Ulrich S ^b   Bauer, Michael ^a,b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c University of North Carolina at Charlotte   (United States)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e Institute for Photonic Technology Jena   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FLUORESCENT DYE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIGAND; NANOPARTICLE; POLYMER; SMALL INTERFERING RNA; INDOLE DERIVATIVE; VPM CHLORIDE;

ACOUSTIC TOMOGRAPHY; DYE; ENZYME ACTIVITY; EXCRETION; FLUORESCENCE; GENE EXPRESSION; NANOTECHNOLOGY; RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE; BILIARY EXCRETION; BODY DISTRIBUTION; CELLS BY BODY ANATOMY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL; LIVER CLEARANCE; LIVER PARENCHYMA; MALE; MICROSCOPY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PHOTOACOUSTIC TOMOGRAPHY; RNA INTERFERENCE; SYNTHESIS; ANIMAL; BLOOD; DRUG DELIVERY SYSTEM; GENETICS; HEK293 CELL LINE; METABOLISM; RAT;

ANIMALS; CHOLESTEROL; DRUG DELIVERY SYSTEMS; FLUORESCENT DYES; HEK293 CELLS; HEPATOCYTES; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; INDOLES; NANOPARTICLES; RATS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84922736573     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6565     Document Type: Article

References (60)

1. de Fougerolles, A., Vornlocher, H. P., Maraganore, J. & Lieberman, J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. 6, 443-453 (2007).
2. Kole, R., Krainer, A. R. & Altman, S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. 11, 125-140 (2012).
3. Davidson, B. L. & McCray, Jr. P. B. Current prospects for RNA interferencebased therapies. Nat. Rev. 12, 329-340 (2011).
4. Dudek, H. et al. Knockdown of b-catenin with dicer-substrate siRNA reduces liver tumor BUrden in vivo. Mol. Ther. 22, 92-101 (2014).
5. Shim, M. S. & Kwon, Y. J. Efficient and targeted delivery of siRNA in vivo. FEBS J. 277, 4814-4827 (2010).
6. Hong, B. J., Chipre, A. J. & Nguyen, S. T. Acid-Degradable Polymer-Caged Lipoplex (PCL) Platform for siRNA Delivery: Facile Cellular Triggered Release of siRNA. J. Am. Chem. Soc. 135, 17655-17658 (2013).
7. David, S., Pitard, B., Benoit, J. P. & Passirani, C. Non-viral nanosystems for systemic siRNA delivery. Pharmacol. Res. 62, 100-114 (2010).
8. Yu, B. et al. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood 121, 136-147 (2013).
9. Recknagel, P. et al. Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis. PLoS Med. 9, e1001338 (2012).
10. Wang, J., Lu, Z., Wientjes, M. G. & Au, J. L. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 12, 492-503 (2010).
11. Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. 8, 129-138 (2009).
12. Qasim, W. & Thrasher, A. J. RISC control for gene therapy. Nat. Biotechnol. 24, 661-662 (2006).
13. Buyens, K. et al. Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. J. Control Release 158, 362-370 (2012).
14. Islam, M. A. et al. Major degradable polycations as carriers for DNA and siRNA. J. Control Release. doi:10. 1016/J. Jcontel. 2014. 05. 055 (in the press).
15. Nishina, K. et al. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol. Ther. 16, 734-740 (2008).
16. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004).
17. Mingozzi, F. & High, K. A. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. 12, 341-355 (2011).
18. Wagner, E. Polymers for siRNA delivery: inspired by viruses to be targeted, dynamic, and precise. Acc. Chem. Res. 45, 1005-1013 (2012).
19. Kay, M. A. State-of-the-art gene-based therapies: the road ahead. Nat. Rev. 12, 316-328 (2011).
20. Ozdemir, V. et al. Shifting emphasis from pharmacogenomics to theragnostics. Nat. Biotechnol. 24, 942-946 (2006).
21. Pan, D. P. J. Theranostic Nanomedicine with Functional Nanoarchitecture. Mol. Pharmaceut. 10, 781-782 (2013).
22. Quaglia, A. et al. Liver after hepatocyte transplantation for liver-based metabolic disorders in children. Cell Transplant. 17, 1403-1414 (2008).
23. Dhawan, A., Mitry, R. R. & Hughes, R. D. Hepatocyte transplantation for liver-based metabolic disorders. J. Inherit. Metab. Dis. 29, 431-435 (2006).
24. Schroit, A. J., Madsen, J. & Nayar, R. Liposome-cell interactions: in vitro discrimination of uptake mechanism and in vivo targeting strategies to mononuclear phagocytes. Chem. Phys. Lipids 40, 373-393 (1986).
25. Sato, A., Takagi, M., Shimamoto, A., Kawakami, S. & Hashida, M. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials 28, 1434-1442 (2007).
26. Akinc, A. et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol. Ther. 17, 872-879 (2009).
27. Roth, M., Araya, J. J., Timmermann, B. N. & Hagenbuch, B. Isolation of modulators of the liver-specific organic anion-transporting polypeptides (OATPs) 1B1 and 1B3 from Rollinia emarginata Schlecht (Annonaceae). J. Pharmacol. Exp. Ther. 339, 624-632 (2011).
28. Stieger, B. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. Handbook of experimental pharmacology 201, 205-259 (2011).
29. Okamoto, E., Kyo, A., Yamanaka, N., Tanaka, N. & Kuwata, K. Prediction of the safe limits of hepatectomy by combined volumetric and functional measurements in patients with impaired hepatic function. Surgery 95, 586-592 (1984).
30. Cherrick, G. R., Stein, S. W., Leevy, C. M. & Davidson, C. S. Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction. J. Clin. Invest. 39, 592-600 (1960).
31. Leevy, C. M., Mendenhall, C. L., Lesko, W. & Howard, M. M. Estimation of hepatic blood flow with indocyanine green. J. Clin. Invest. 41, 1169-1179 (1962).
32. Recknagel, P., Claus, R. A., Neugebauer, U., Bauer, M. & Gonnert, F. A. In vivo imaging of hepatic excretory function in the rat by fluorescence microscopy. J. Biophoton 5, 571-581 (2012).
33. Huang, S-M., Temple, R., Throckmorton, D. C. & Lesko, L. J. Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and LabelingPublic Policy. Clin. Pharmacol. Ther. 81, 298-304 (2007).
34. Burchard, W. Solution properties of branched macromolecules. Adv. Polym. Sci. 143, 113-194 (1999).
35. Gurcel, L., Abrami, L., Girardin, S., Tschopp, J. & van der Goot, F. G. Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival. Cell 126, 1135-1145 (2006).
36. Chumakova, O. V. et al. Composition of PLGA and PEI/DNA nanoparticles improves ultrasound-mediated gene delivery in solid tumors in vivo. Cancer Lett. 261, 215-225 (2008).
37. Liang, G. F. et al. PLGA-based gene delivering nanoparticle enhance suppression effect of miRNA in HePG2 cells. Nanoscale Res. Lett. 6, 447 (2011).
38. Patil, Y. & Panyam, J. Polymeric nanoparticles for siRNA delivery and gene silencing. Int. J. Pharm. 367, 195-203 (2009).
39. Su, W. P., Cheng, F. Y., Shieh, D. B., Yeh, C. S. & Su, W. C. PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int. J. Nanomed. 7, 4269-4283 (2012).
40. Karlgren, M. et al. In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharm. Res. 29, 411-426 (2012).
41. Dahlman, J. E. et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat. Biotechnol. 9, 648-655 (2014).
42. Cartiera, M. S., Johnson, K. M., Rajendran, V., Caplan, M. J. & Saltzman, W. M. The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials 30, 2790-2798 (2009).
43. Panyam, J., Zhou, W. Z., Prabha, S., Sahoo, S. K. & Labhasetwar, V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 16, 1217-1226 (2002).
44. Gilleron, J. et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31, 638-646 (2013).
45. Puri, V. et al. Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseases. Nat. Cell Biol. 1, 386-388 (1999).
46. Weber, M. et al. Hepatic induction of cholesterol biosynthesis reflects a remote adaptive response to pneumococcal pneumonia. FASEB J. 26, 2424-2436 (2012).
47. Neijssen, J. et al. Cross-presentation by intercellular peptide transfer through gap junctions. Nature 434, 83-88 (2005).
48. De Maio, A., Gingalewski, C., Theodorakis, N. G. & Clemens, M. G. Interruption of hepatic gap junctional communication in the rat during inflammation induced by bacterial lipopolysaccharide. Shock 14, 53-59 (2000).
49. Kamps, J. A., Morselt, H. W., Swart, P. J., Meijer, D. K. & Scherphof, G. L. Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells. Proc. Natl Acad. Sci. USA 94, 11681-11685 (1997).
50. Su, R., Ermilov, S. A., Liopo, A. V. & Oraevsky, A. A. Three-dimensional optoacoustic imaging as a new noninvasive technique to study long-term biodistribution of optical contrast agents in small animal models. J. Biomed. Opt. 17, 101506 (2012).
51. Tsyboulski, D. A. et al. Enabling in vivo measurements of nanoparticle concentrations with three-dimensional optoacoustic tomography. J. Biophoton. 7, 581-588 (2014).
52. Wang, L. V. & Hu, S. Photoacoustic tomography: in vivo imaging from organelles to organs. Science 335, 1458-1462 (2012).
53. Cohen, J. L. et al. Acetal-modified dextran particles for siRNA delivery. Bioconj. Chem. 22, 1056-1065 (2011).
54. Rinkenauer, A. C. et al. Parallel high-throughput screening of polymer vectors for nonviral gene delivery: evaluation of structure-property relationships of transfection. ACS Comb. Sci. 15, 475-482 (2013).
55. Chen, P. S., Toribara, T. Y. & Warner, H. Microdetermination of phosphorus. Anal. Chem. 28, 1756-1758 (1956).
56. Razansky, D., Buehler, A. & Ntziachristos, V. Volumetric real-time multispectral optoacoustic tomography of biomarkers. Nat. Protocol. 6, 1121-1129 (2011).
57. Sarantopoulos, A., Themelis, G. & Ntziachristos, V. Imaging the biodistribution of fluorescent probes using multispectral epi-illumination cryoslicing imaging. Mol. Imaging Biol. 13, 874-885 (2011).
58. Gripon, P. et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl Acad. Sci. USA 99, 15655-15660 (2002).
59. Schwintzer, L. et al. The functions of the actin nucleator Cobl in cellular morphogenesis critically depend on syndapin I. EMBO J. 30, 3147-3159 (2011).
60. Dharmalingam, E. et al. F-BAR proteins of the syndapin family shape the plasma membrane and are crucial for neuromorphogenesis. J. Neurosci. 29, 13315-13327 (2009).